MFN changing the rules of the game for the Nordic countries
Recent GlobalData POLI analysis showed a 35% decline in pharmaceutical launches across Europe in the ten months after the introduction of IRP in the US.
Pricing and Market Access
The Most Favored Nation Policy: early insights into Europe’s response
GlobalData’s key thoughts from World EPA Congress 2026
Market instability expected from South Korea’s new pricing reform in 2026-2028
Have originator medicines’ list prices started to drop in the US?
Transformative arrival of oral weight loss medicines in the US
US comes up with two mandatory IRP use pricing models under Trump’s MFN strategy
China releases 2025 NRDL and first commercial insurance drug list
